305 related articles for article (PubMed ID: 9578088)
1. Fas ligand expression in nodal non-Hodgkin's lymphoma.
Müllauer L; Mosberger I; Chott A
Mod Pathol; 1998 Apr; 11(4):369-75. PubMed ID: 9578088
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
Nguyen PL; Harris NL; Ritz J; Robertson MJ
Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
[TBL] [Abstract][Full Text] [Related]
3. Preferential expression of the mucosal homing receptor integrin alpha 4 beta 7 in gastrointestinal non-Hodgkin's lymphomas.
Drillenburg P; van der Voort R; Koopman G; Dragosics B; van Krieken JH; Kluin P; Meenan J; Lazarovits AI; Radaszkiewicz T; Pals ST
Am J Pathol; 1997 Mar; 150(3):919-27. PubMed ID: 9060830
[TBL] [Abstract][Full Text] [Related]
4. CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.
Bellan C; De Falco G; Lazzi S; Micheli P; Vicidomini S; Schürfeld K; Amato T; Palumbo A; Bagella L; Sabattini E; Bartolommei S; Hummel M; Pileri S; Tosi P; Leoncini L; Giordano A
J Pathol; 2004 Aug; 203(4):946-52. PubMed ID: 15258998
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
6. Clusterin expression in malignant lymphomas: a survey of 266 cases.
Saffer H; Wahed A; Rassidakis GZ; Medeiros LJ
Mod Pathol; 2002 Nov; 15(11):1221-6. PubMed ID: 12429802
[TBL] [Abstract][Full Text] [Related]
7. TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation.
Felgar RE; Macon WR; Kinney MC; Roberts S; Pasha T; Salhany KE
Am J Pathol; 1997 Jun; 150(6):1893-900. PubMed ID: 9176382
[TBL] [Abstract][Full Text] [Related]
8. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
9. [Paraneoplastic lymphadenopathy].
Melikian AL; Nikitin EA; Kaplanskaia IB; Frank GA
Ter Arkh; 2007; 79(8):44-52. PubMed ID: 17926471
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotypic analysis of extranodal non-Hodgkin's lymphomas in the oral cavity.
Takahashi H; Fujita S; Okabe H; Tsuda N; Tezuka F
Pathol Res Pract; 1993 Apr; 189(3):300-11. PubMed ID: 8332573
[TBL] [Abstract][Full Text] [Related]
11. [R.E.A.L. classification of non-Hodgkin lymphoma from the clinico-oncologic viewpoint].
Meusers P; Brittinger G
Praxis (Bern 1994); 1998 Jun; 87(23):793-800. PubMed ID: 9654985
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of a new CD5 antibody for the diagnosis of T-cell and B-cell lymphoproliferative disorders in paraffin sections.
Dorfman DM; Shahsafaei A
Mod Pathol; 1997 Sep; 10(9):859-63. PubMed ID: 9310947
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
14. [The morphological diagnosis of malignant non-Hodgkin's lymphomas (lymphosarcomas)].
Probatova NA
Arkh Patol; 1990; 52(9):72-5. PubMed ID: 2270988
[TBL] [Abstract][Full Text] [Related]
15. [The results of histological and immunohistological studies of primary biopsies in 400 patients with non-Hodgkin's lymphoma in the North-West region of Russia (according to WHO classification)].
Krivolapov IuA
Ter Arkh; 2004; 76(7):64-70. PubMed ID: 15379131
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas.
Kovalevska LM; Yurchenko OV; Shlapatska LM; Berdova GG; Mikhalap SV; Van Lint J; Sidorenko SP
Exp Oncol; 2006 Sep; 28(3):225-30. PubMed ID: 17080017
[TBL] [Abstract][Full Text] [Related]
17. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.
Coupland SE; Foss HD; Assaf C; Auw-Haedrich C; Anastassiou G; Anagnostopoulos I; Hummel M; Karesh JW; Lee WR; Stein H
Ophthalmology; 1999 Nov; 106(11):2109-20. PubMed ID: 10571346
[TBL] [Abstract][Full Text] [Related]
18. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fas and Fas ligand in cutaneous B-cell lymphomas.
Zoi-Toli O; Meijer CJ; Oudejans JJ; de Vries E; van Beek P; Willemze R
J Pathol; 1999 Dec; 189(4):533-8. PubMed ID: 10629554
[TBL] [Abstract][Full Text] [Related]
20. Fas/Fas ligand interactions are involved in ultraviolet-B-induced human lymphocyte apoptosis.
Caricchio R; Reap EA; Cohen PL
J Immunol; 1998 Jul; 161(1):241-51. PubMed ID: 9647230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
